Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Ocular Therapeutix (OCUL) Enterprise Value (2016 - 2026)

Ocular Therapeutix has reported Enterprise Value over the past 14 years, most recently at -$666.7 million for Q1 2026.

  • For Q1 2026, Enterprise Value fell 90.66% year-over-year to -$666.7 million; the TTM value through Mar 2026 reached -$666.7 million, down 90.66%, while the annual FY2025 figure was -$737.1 million, 87.98% down from the prior year.
  • Enterprise Value for Q1 2026 was -$666.7 million at Ocular Therapeutix, up from -$737.1 million in the prior quarter.
  • Over five years, Enterprise Value peaked at -$66.6 million in Q2 2023 and troughed at -$737.1 million in Q4 2025.
  • A 5-year average of -$306.3 million and a median of -$344.8 million in 2025 define the central range for Enterprise Value.
  • Biggest five-year swings in Enterprise Value: skyrocketed 50.49% in 2023 and later plummeted 590.16% in 2024.
  • Year by year, Enterprise Value stood at -$102.3 million in 2022, then tumbled by 91.55% to -$196.0 million in 2023, then crashed by 100.1% to -$392.1 million in 2024, then crashed by 87.98% to -$737.1 million in 2025, then grew by 9.55% to -$666.7 million in 2026.
  • Business Quant data shows Enterprise Value for OCUL at -$666.7 million in Q1 2026, -$737.1 million in Q4 2025, and -$344.8 million in Q3 2025.